The Latest Breaking News from MRK

Merck & Co Inc (NYSE:MRK) and Ridgeback Biotherapeutics announced that the Annals of Internal Medicine had published additional data from the Phase 3 MOVe-OUT trial of Lagevrio (molnupiravir) in non-hospitalized COVID-19 patients at high risk for progressing to severe disease. A lower proportion of molnupiravir-treated participants in the modified intent-to-treat population had an acute care…

A whale with a lot of money to spend has taken a noticeably bearish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 14 strange trades.

The stock market closed the last trading session of May in the red, underscoring inflation fears and rising oil prices. Furthermore, strategists expect the broad market to decline further, given the inflationary pressures and the Fed’s monetary tightening. Hence, we think stocks that have outpaced the broader market so far…

It's great for a stock to rise in a weak market. But if the market strengthens, its contrarian nature may work against it.

The Fed’s aggressive interest rate increases to tame multi-decade high inflation, and an anticipated economic slowdown, have exacerbated market volatility of late. To protect against the market uncertainties, we think investors should consider investing in low-beta stocks Merck (MRK), Gilead Sciences (GILD), and AmerisourceBergen (ABC). Let’s discuss why.

European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending Merck & Co Inc (NYSE:MRK) Keytruda in melanoma setting. The opinion covers Keytruda as a monotherapy adjuvant treatment for adults and adolescents aged 12 years and older with stage IIB or IIC melanoma and who have…

Someone with a lot of money to spend has taken a bearish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

A rally attempt is underway. Get ready, get set, but don't go just yet. Chevron, Broadcom, Tesla and Twitter are among stocks to watch.

The stock market tumbled Wednesday on a hot inflation report. A lack of investor fear suggests no market bottom yet.

Futures rise on hopes inflation has peaked with April CPI data due before the open. Two more big Ark holdings dived.

Given current market volatility due to concerns over the Fed's tighter monetary policy to tame surging inflation and fears of an economic slowdown, we think investors should consider buying stocks with sound fundamentals and solid growth attributes. Nutrien (NTR), Merck & Co (MRK), and Bunge (BG) recently reported promising quarterly…